Jazz Pharmaceuticals plc

Equities

JAZZ

IE00B4Q5ZN47

Market Closed - Nasdaq Other stock markets 04:00:00 2025-12-12 pm EST			5-day change	1st Jan Change
167.50 ^USD	+1.58%		-1.30%	+36.01%

Dec. 11	Jazz Pharmaceuticals Insider Sold Shares Worth $379,366, According to a Recent SEC Filing	MT
Dec. 10	This Is Decision Day

Transcript : Jazz Pharmaceuticals plc, Q3 2025 Earnings Call, Nov 05, 2025

Published on 11/05/2025 at 07:00 pm EST - Modified on 11/05/2025 at 08:36 pm EST

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good day, and thank you for standing by. Welcome to the Jazz Pharmaceuticals 2025 Third Quarter Earnings Conference Call. [Operator Instructions]

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Jazz Pharmaceuticals plc

Dec. 11	Jazz Pharmaceuticals Insider Sold Shares Worth $379,366, According to a Recent SEC Filing	MT
Dec. 10	This Is Decision Day
Dec. 10	Analyst recommendations: Abbvie, Biogen, PepsiCo, Eli Lilly, Netflix…
Dec. 09	Jazz Pharmaceuticals Insider Sold Shares Worth $797,783, According to a Recent SEC Filing	MT
Dec. 05	Jazz Pharmaceuticals plc to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex®? (Cannabidiol) Outcomes in Treatment-Resistant Epilepsies At the American Epilepsy Society 2025 Annual Meeting	CI
Dec. 02	Jazz Pharmaceuticals plc to Present Pivotal Phase 3 Results of Ziihera®? (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCOGastrointestinal Cancers Symposium	CI
Dec. 02	Jazz Pharmaceuticals plc Presents at Citi Annual Global Healthcare Conference 2025, Dec-02-2025 09:45 AM
Dec. 02	Jazz Pharmaceuticals Insider Sold Shares Worth $13,780,337, According to a Recent SEC Filing	MT
Nov. 27	Stockholm Bullets – Arise Soars on Takeover Bid	FW
Nov. 27	Saniona Reports Operating Profit of SEK 360 Million	FW
Nov. 24	Jazz Pharmaceuticals Insider Sold Shares Worth $607,127, According to a Recent SEC Filing	MT
Nov. 24	Jazz Gains From Ziihera Data, Upside Seen as Priced In, UBS Says	MT
Nov. 24	UBS Downgrades Jazz Pharmaceuticals to Neutral From Buy, Raises Price Target to $188 From $163	MT
Nov. 21	Jazz Pharmaceuticals Insider Sold Shares Worth $3,259,538, According to a Recent SEC Filing	MT
Nov. 20	Jazz Pharmaceuticals Insider Sold Shares Worth $1,204,573, According to a Recent SEC Filing	MT
Nov. 19	Truist Adjusts Price Target on Jazz Pharmaceuticals Public to $220 From $205, Maintains Buy Rating	MT
Nov. 18	Traders Strap In, Again
Nov. 18	Deutsche Bank Raises Price Target on Jazz Pharmaceuticals to $210 From $173, Keeps Buy Rating	MT
Nov. 18	Analyst recommendations: Alphabet, Amazon, Microsoft, AbbVie, Comcast…
Nov. 18	Zymeworks Commences Strategic Initiative for Licensed Products to Enhance Future Cash Flows	MT
Nov. 17	Top Midday Gainers	MT
Nov. 17	Beone Medicines Ltd. Announces Positive Phase 3 Results Support Ziihera® as Her2-Targeted Therapy-Of-Choice and Combination with Tevimbra and Chemotherapy as New Standard of Care in First-Line Her2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma	CI
Nov. 17	Top Midday Stories: Amazon to Sell Used Ford Vehicles on Website; Novo Nordisk Cuts Wegovy, Ozempic Prices	MT
Nov. 17	Sector Update: Health Care Stocks Mixed Pre-Bell Monday	MT
Nov. 17	Sector Update: Health Care	MT